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We found that hyperactivation of cytoplasmic (anti-inflammatory) and mitochondrial (pro-inflammatory) arginase 
isoforms in peripheral blood leukocytes (PBL) is more pronounced in women than in male patients with type 1 diabetes 
mellitus (T1DM) who received insulin for one year, especially in adolescents young adults 15 years old (12.0 - 25.0) 
compared with children/adolescents 9.3 years old (4.5-11.8). Long-term treatment with insulin up to 14 years (on average 
5.3-5.9) reduces the activity of arginase, especially in puberty girls with a tendency to normalize mitochondrial arginase, 
while in prepubertal boys the activity of both arginase isoforms almost doubles and remains elevated in puberty boys and 
can be involved in inhibiting nitric oxide synthase (NOS) and decreasing the bioavailability of NO. This is confirmed by the 
concomitant continuous decrease in the levels of nitric oxide synthase (NOS) products, stable metabolites of NO (nitrite) 
and L-citrulline in the cytoplasm and mitochondria of PBL in prepubertal girls and boys, in the latter, regardless of age and 
insulin therapy, while in girls of puberty changes not found, apparently, due to the increased level of sex hormones that 
promote the expression and activity of NOS, which contribute to the inhibition of arginase. Further studies are needed to 
understand whether sex and age-related changes found in L-arginine metabolism in PBL can be useful in assessing the stage 
and progression of T1DM and the effectiveness of therapy.  
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Type 1 diabetes mellitus (T1DM) is characterized by 
autoimmune destruction of insulin-producing pancreatic 
β-cells and systemic metabolic derangements1,2. A 
steady rise in the incidence of T1DM is happening 
globally, including Armenia3,4. Despite advances in 
insulin therapies, often glucose homeostasis cannot be 
restored, and subsequent common complications 
occur5,6. Interest in novel therapies for T1DM has grown 
in the past years and is supported by encouraging data 
on its metabolic control to overcome the autoimmune 
processes and disordered immunoregulation1,7. The 
induction and expansion of inflammatory cytokines and 
immune cells (T helper lymphocytes (Th), macrophages, 
dendritic cells, etc.) are accompanied by the production 
of reactive oxygen and nitrogen species, peroxynitrite 
and nitric oxide (NO), produced by constitutive and 
inducible NO. synthases (NOS) in the leukocyte and  
β-cell and contribute to the inhibition of insulin secretion 
by nitrosylation of proteins and the generation of 
neoantigens, leading to the destruction of pancreatic  
β-cells in patients with T1DM8,9. Inflammatory agents 
and oxidative/nitrosative stress stimulate the expression 
and activity of arginase isoforms10. It is noteworthy,  
that arginase is activated by peroxynitrite-mediated 
RhoA/Rho kinase signaling pathway, and their 
inhibition has a cardioprotective effect in T1DM11,12. 
Arginase and NOS are reciprocally regulated, 
sharing a common substrate, L-arginine, and are 
involved in the mechanisms of autoimmunity and 
immunosuppression12,13. The balance between the 
enzymes is competitively regulated by Th1 and Th2 
lymphocytes, respectively, up-regulating inducible 
NOS (iNOS) and arginase and affecting the dichotomy 
of the macrophage M1/M2, i.e. M1 phenotype 
expressing iNOS for killing / fighting, against the M2 
phenotype expressing A1 for healing/fixing14,15. Insulin 
can inhibit the development of diabetes by altering the 
balance in the islets from Th1 in destructive insulitis to 
Th2 in benign insulitis16. In turn, iNOS and arginase 
can also affect Th1/Th2 balance and macrophage 
differentiation and delay the development of 
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T1DM17,18. Arginase can limit the level of L-arginine, 
which is an important metabolic modulator of 
macrophage and T cell functions19. L-arginine can also 
increase insulin and glucose levels, especially in 
plasma, both by NO-dependent and NO-independent 
mechanisms20. It is necessary for the growth of infants 
and children and promotes the expression and synthesis 
of insulin-like growth factor 1 (IGF-1)21. It is 
noteworthy that the L-arginine/NO pathway is affected 
in children and adolescents and is different from adults 
with T1DM22. The higher levels of glycated 
hemoglobin (HbA1c) detected in pre- and early puberty 
is associated with lower levels of IGF-1, which 
increases at higher doses of insulin, especially during 
puberty, and particularly in women with T1DM23. 
Differences in the immune systems of men and women 
play a crucial role in autoimmune diseases, including 
the severity and course of the disease, response to 
therapy, and overall survival24. However, sex and  
age-related differences in the metabolism of L-arginine 
in T1DM, and especially those associated with  
puberty, need to be elucidated. Our work is devoted  
to the study of issues related to sex and puberty 
associated differences in the metabolism of L-arginine 
in peripheral blood leukocytes (PBL) and plasma, as 
well as the effect of insulin treatment in young 
Caucasians with T1DM, which may be useful for 
assessing the stage and progression of T1DM in 
humans25. 
 
Materials and Methods 
Chemicals 
Dextran (Mr 100 000), diacetylmonoxime and 
bovine serum albumin were purchased from Carl Roth 
(GmbH, Karlsruhe, Germany). L-arginine∙HCl, HEPES, 
(6R)-5,6,7,8-tetrahydro-L-biopterin dihydrochloride, 
2(S)-amino-6-boronohexanoic acid, NADPH, FAD, 
FMN, ninhydrin and other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA) and Reanal 
(Hungary). 
 
Participants  
All patients with T1DM were recruited from Muratsan 
University Hospital, Department of Endocrinology 
(Yerevan, Armenia). The study population involved  
270 Caucasians aged 4-22 years with newly diagnosed 
T1DM (duration up to one year from the time of the first 
manifestation) (male n=47, female n=44), and long-term 
T1DM (duration more than one year up to 14 years 
(male n=46, female n=40) and age- and sex-matched 
healthy volunteers (male n=46, female n=47). The 
informed consent was obtained from all participants 
studied in accordance with Good Clinical Practice 
(GCP) standards and the WMA Declaration of Helsinki 
- Ethical Principles for Medical Research Involving 
Human Subjects26. The study was approved by the 
Ethics Committee of the Yerevan State Medical 
University after Mkhitar Heratsi. Patients with T1DM 
were diagnosed according to guidelines of American 
DiabetesAssociation27. At least two types of antibodies 
described in association with the development of T1DM 
- islet cell autoantibodies to insulin and glutamic acid 
decarboxylase – were positive at the time of diagnosis of 
T1DM. The exclusion criteria were macrovascular and 
microvascular (retinopathy, nephropathy) diseases, 
acute or chronic liver, kidney or cardiac diseases, 
malignancy, arterial hypertension, pregnancy. Diabetic 
patients were treated and monitored according to the 
standard medical protocol. 
 
Procedures  
Procedures were performed at the Department of 
Endocrinology of “Muratsan” University Hospital 
(Yerevan, Armenia). All patients received multiple daily 
insulin injections. The absence of microalbuminuria was 
determined by measurement of urinary albumin/ 
creatinine ratio, and of macro-vascular disease by the 
absence of a cardiovascular event or procedure, angina, 
ischemic ECG abnormalities. All the participants were 
examined early in the morning, fasted, having avoided 
caffeinated beverages, cigarettes and strenuous exercise 
since the previous evening. 
 
Plasma HbA1c  
Plasma HbA1c was measured at “Muratsan” Hospital 
clinical laboratory by a latex turbidimetric assay and 
marked as a percentage (%)28. 
 
Blood leukocyte and plasma isolation 
Freshly obtained peripheral venous blood was anti-
coagulated using 3.9% sodium citrate (C6H9Na·5H2O), 
mixed with 6% dextran (Mr 100000, prepared  
with 0.9% NaCl) and incubated at 37°C for 60 min to 
remove red blood cells by gravity sedimentation.  
The layer containing plasma with leukocytes and 
platelets was decanted and centrifuged at 1000 rpm for  
5 min, and precipitated leukocytes were washed twice 
before use, the supernatant was centrifuged at 6000 rpm 
for 20 min at 4°C to separate plasma from platelets29. 
 
Leukocyte cytoplasmic and mitochondrial fractions  
Leukocyte cytoplasmic and mitochondrial fractions 
were obtained by differential centrifugation of the 
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leukocyte homogenates30. Leukocytes were resuspended 
in ice-cold 20 mM HEPES buffer pH 7.4, containing 
0.25 M sucrose, (1:10, w/v) and homogenized using 
Potter homogenizer (1500 rpm for 3 min). Homogenates 
were centrifuged at 1200 rpm for 10 min at 4°C to 
remove nuclei and cell debris. Pellet was discarded 
and the supernatant further centrifuged at 11000 rpm 
for 20 min at 4°С to yield the cytoplasm in the 
supernatant and the crude mitochondrial preparation 
in the pellet, which was washed twice, resuspended 
and homogenized in the buffer used.  
 
Arginase assay 
The samples were added to the reaction mixture:  
20 mM HEPES buffer (pH 7.4), 3.9 mM 
MnCl2·4H2O, 15.4 mM L-arginine·HCl, incubated at 
37°C for 60 min, followed by the addition of 10% 
TCA to stop the reaction31. Control experiments were 
conducted in the presence of 2(S)-amino-6-
boronohexanoic acid hydrochloride the most potent, 
stable, and specific arginase inhibitor, which in vivo 
effectively blocks arginase activity and does not 
inhibit the NOS32. After centrifugation (15000 rpm,  
3 min) protein-free supernatants were sampled and 
analyzed for L-ornithine content. The arginase activity 
is expressed as produced in an hour L-ornithine per mg 
of total protein. 
 
Measurement of L-ornithine 
Samples were mixed with 4.5% ninhydrin solution 
and heated (90°C, 20 min), then cooled to the room 
temperature and the absorbance was measured at  
505 nm wavelength against blank control containing 
all the reagents minus the sample31. 
 
Measurement of nitrite 
Samples deproteinized with 0.5 N NaOH and 10% 
ZnSO4·7H2O, were centrifuged (15000 rpm, 3 min), 
and the protein-free supernatants were sampled and 
analyzed for nitrite using colorimetric technique 
based on diazotization reaction with Griess reagent 
and measured at 546 nm wavelength against blank 
control containing all the reagents minus the sample33. 
 
Measurement of L-citrulline 
Samples deproteinized with 10% TCA, centrifuged 
(15000 rpm, 3 min), and the protein-free supernatants 
were mixed with reagent (mixture of equal amounts 
of 9.6% H2SO4 and freshly prepared solution (5 mМ 
diacetylmonoxime, 0.9 mM thiosemicarbazide,and 
0.025 mМ FeCl3, 1:1:1, v/v), heated in a boiling water 
bath for 10 min, cooled to the room temperature and 
the absorbance was measured at 490 nm wavelength 
against blank control containing all the reagents 
minus the sample34. 
Protein  
Protein was determined using crystalline bovine 
serum albumin as standard35. 
 
Statistical analysis 
The results were expressed as the mean (M) ± 
standard error of the mean (SEM). The differences 
among many groups were analyzed by analysis of 
variance (one-way ANOVA), followed by Holm-
Sidak post hoc test. Comparisons between two groups 
were analyzed using Student’s t-tests. P-value <0.05 
was considered significantly different. 
 
Results  
Complex changes occur during T1DM in the 
differentiation and functioning of immune cells with 
the involvement of myeloid suppressor cells, 
macrophages, T-helper lymphocytes, etc.36,37. 
Therefore, we studied all subsets of peripheral blood 
leukocytes (PBL) to evaluate the overall picture of the 
immune response associated with the metabolism of 
L-arginine in the blood of patients with T1DM. We 
examined newly diagnosed (ND) non-treated patients 
with the first manifestation of T1DM (ND/NT), and 
those treated with insulin for up to one year (average 
0.5-0.6 years) (ND/T), and treated for up to 14 years 
(average 5.3-5.9 years), i.e., long-term treatment 
(LT/T). Patients were differentiated by sex and age: 
T1DM-FI - children/preadolescent females; T1DM-
FII - adolescents/young females; T1DM-MI - children 
/preadolescent males; T1DM-MII - adolescents/young 
males, and healthy controls (HC) of corresponding 
sex and age. Clinical data and information regarding 
the T1DM patients, and HC are presented in the 
(Tables 1 & 2). 
Arginase isoforms activity was measured in the 
cytoplasm (A1) and mitochondria (A2) of PBL in the 
mentioned above groups (Fig. 1). In the T1DM-FI 
group, at the first manifestation of T1DM (ND/NT) 
the activity of A1 remained the same and that of A2 
only slightly increased, while after treatment in ND/T 
females the activity of A1 and A2 increased 2 and  
2.4 times, respectively, resulting in the shift of 
balance towards A2, the activity of which became  
1.5 times higher than that of A1 (P <0.001). These 
changes are important if we take into account 
different roles of arginase isoforms, as well as their 
opposite regulation of macrophage functions38.  
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In long-term treated LT/T female patients, increased 
A1 activity remained, while A2 activity decreased, 
but was 1.4 times higher than in HC. Unlike 
children/preadolescent females, in the T1DM-FII 
group, arginase isoforms were activated in the cellular 
compartments of PBL at the first manifestation of 
T1DM. Moreover, the activity of A1 increased 1.95, 
3.28, and 2 times in ND/NT, ND/T, and LT/T 
patients, respectively, compared with HC. The A2 
activity also increased 1.3 and 2.8 times in ND/NT 
and ND/T patients, respectively, but normalized after 
prolonged treatment with insulin, resulting in the shift 
of balance towards A1, the activity of which was  
1.5 times higher than that of A2 (P=0.003). Thus, long-
term insulin treatment modulated the activity of A2 in 
children/preadolescent females and regulated the activity 
of both arginase isoforms in adolescents/young females. 
In the T1DM-MI group, the activity of A1 and A2 
increased by about 1.8 times in PBL at the first 
manifestation of diabetes and after treatment in ND/T 
male patients, remained basically at that level, while 
in long-term treated LT/T patients, their activity 
stimulated by about 2.5 times, compared with HC. In 
the T1DM-MII group, a less pronounced increase in 
the activity of arginase isoforms was observed, which 
increased about 1.5, 1.8, and 1.7 times in ND/NT, 
ND/T, and LT/T patients, respectively, compared with 
HC. Thus, in both age groups of male patients, insulin 
therapy did not reduce the time-dependent increase 
increase in the activity of arginase isoforms. 
Sex- and age-dependent changes in the total 
activity of arginase in the blood plasma of patients 
with T1DM are presented in (Fig. 2). Interestingly, 
the activity of arginase remained unchanged in the 
plasma of female patients with T1DM in both age 
groups, both at the first manifestation of the disease, 
and after treatment with insulin, regardless of the 
duration, although it increased 1.4-fold in ND/T 
adolescents/young females, compared with HC. In the 
T1DM-MI group, plasma arginase activity increased 
2.2, 1.7, and 2.1 times in ND/NT, ND/T, and LT/T 
children/preadolescent males, respectively, compared 
with HC, whereas, in the T1DM-MII group, it remained 
unchanged. 
Table 1 — Clinical data of children/preadolscents with newly diagnosed T1DM (T1DM-ND) and long-term  
T1DM (T1DM-LT) and healthy controls (HC) 
Variable T1DM-ND T1DM-LT HC 
Number of subjects 47 43 46 
Male/female 24/23 23/20 24/22 
The first manifestation/ up to a year Male//female  10/14//9/14 - - 
Age (years), median (range) 9.4 [5.3-11.5] 9.3 [4.5-11.8] 9.5 [4.0-11.5] 
Age of debut (years), median (range) 8.0 [4.5-11.2] 6.1 [1.7-10.2] - 
Diabetes duration (years), median (range) 0.5 [0.01-1.0] 5.3 [1.6-9.1] - 
HbA1C (% ), median (range) 8.0 [5.6-13.4] 7.3 [6.6-12.7] 4.7 [4.0-5.3] 
BMI (kg/m2), median (range) 17.4 [14.9-22.1] 17.6 [15.1-21.0] 17.5 [15.1-23.0] 
Cholesterol (mg/dL), median (range) 169 [141-192] 175 [145-197] 155 [137-175] 
Triglycerides (mg/dL), median (range) 89 [71-105] 97 [72- 117] 79 [67-99] 
Creatinine clearance (mL/min), median (range) 115 [95-128] 113 [89-133] 117 [99-133] 
 
Table 2 — Clinical data of adolescents/young adults with newly diagnosed T1DM (T1DM-ND) and long-term  
T1DM (T1DM-LT) and healthy controls (HC) 
Variable T1DM-ND T1DM-LT HC 
Number of children  44 43 47 
Male/female 23/21 23/20 22/25 
The first manifestation/up to a year Male//female 9/14//9/12 - - 
Age (years), median (range) 15.0 [12.0-22.1] 14.5 [12.2-20.7] 15.5 [12.2-21.5] 
Age of debut (years), median (range) 13.9 [10.2-21.2] 10.4 [1.4-20.9] - 
Diabetes duration (years), median (range) 0.6 [0.1-1.0] 5.9 [1.8-9.9] - 
HbA1C (% ), median (range) 8.9 [5,7-16.0] 8.5 [5.9-12.4] 4.8 [4.1-5.4] 
BMI (kg/m2), median (range) 19.0 [14.7-23.7] 19.7 [16.6-23.8] 20.6 [17.9-23.7] 
Cholesterol (mg/dL), median (range) 168 [ 141-193] 177 [143-199] 159 [133-179] 
Triglycerides (mg/dL), median (range) 85 [65-107] 92 [69-115] 81 [63-107] 
Creatinine clearance (mL/min), median (range) 113 [94-127] 111 [91-132] 116 [98-129] 
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It was previously found that plasma arginase 
activation correlates with the degree of hyperglycemia 
and decreases markedly during 4 h of insulin infusion in 
patients with type 2 diabetes39.In our study, only in 
adolescents/young females, insulin could efficiently 
modulate arginase activity in the cellular compartments 
of PBL.  
L-arginine is converted to L-ornithine and urea 
through arginase, and to NO and L-citrulline through 
NOS, and these metabolites are involved in the 
interaction of enzymes40. Nitric oxide is rapidly 
oxidized in vivo to nitrite and nitrate, which circulate 
in the blood and are commonly used to measure NO 
synthesis41. Sex and age-associated changes in the 
levels of nitrite and L-citrulline were examined in the 
blood of patients with T1DM to evaluate the activity 
of the nitrergic system. Nitrites measured in the 
cytoplasm and mitochondria of PBL and plasma in 
healthy children/preadolescent females were 1.8, 1.5, 
and 1.4 times higher, respectively, compared with 
adolescents/young females. This, apparently, is 
associated with a higher level of reactive oxygen 
species (ROS) in their blood, which are involved in 
the formation of peroxynitrite (ONOO–) and reduce 
the bioavailability of NO42. Circulating levels of 
oxidative stress markers are higher in women than in 
men, who, in turn, have circulating concentrations of 
IL-8, IL-6, and TNF-α higher than women43. Our data 
showed that nitrite levels in the cytoplasm of PBL and 
plasma in healthy adolescents/young males are 1.4 and 
2 times higher than in children/preadolescent males. 
Whether this is due to age-dependent activation of 
inducible NOS by TNF-α should be further investigated. 
Sex- and age-dependent changes in nitrite levels in 
the cellular compartments of PBL in patients with 
T1DM are presented in (Fig. 3). In the T1DM-FI 
group, the levels of nitrite decreased 2.5, 2.0, and 1.9 
times in the cytoplasm and 2.3, 1.9 and 1.9 times in 
 
Fig. 1 — Effect of insulin therapy on arginase activity in the cell 
compartments of peripheral blood leukocytes of patients with 
T1DM. Hereinafter, the probability (P) is presented as # P >0.05, 
* P <0.05, ** P <0.01, *** P <0.001 in comparison with healthy 
controls. 
 
 
 
Fig. 2 — Effect of insulin therapy on arginase activity in 
peripheral blood plasma of patients with T1DM. 
 
Fig. 3 — Effect of insulin therapy on nitrite level in the cell 
compartments of peripheral blood leukocytes of patients with T1DM. 
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mitochondria, in ND/NT, ND/T and LT/T female 
patients, respectively, compared with HC. In the 
T1DM-FII group, nitrite levels remained unchanged 
in the cytoplasm, but decreased in mitochondria 1.5, 
1.2 and 1.3 times in ND/NT, ND/T, and LT/T 
females, respectively, compared with HC.  
Thus, in children/preadolescent females, there is a 
persistent decrease in the levels of nitrite in the 
cellular compartments of PBL, which is somewhat 
attenuated by treatment with insulin. In adolescent/ 
young females with T1DM, changes in nitrite levels 
were detected only in the mitochondria and were less 
pronounced. It can be assumed that this is due to  
age-related differences in the share of macrophages 
M2 generating small amounts of NO and large 
quantities of L-ornithine from the same substrate  
L-arginine through arginase44. In addition, in 
adolescents/young females, elevated estrogen levels 
can prevent a drop in NO/nitrite levels affecting the 
expression and function of NADPH oxidases, as well 
as the activity of antioxidant enzymes, inhibiting the 
interaction of O2•– and NO and increasing the 
bioavailability of NO45. 
In the T1DM-MI group, at the first manifestation 
of T1DM, nitrite levels increased 1.9 and 1.5 times in 
the cytoplasm and mitochondria of PBL, as well as two 
times in plasma (vide infra). In ND/T male patients, 
nitrite level decreased 1.3 times in the cytoplasm and 
normalized in mitochondria, whereas in LT/T patients 
their levels decreased 1.5 and 1.8 times in the 
cytoplasm and mitochondria, respectively, compared 
with HC. In the T1DM-MII group, the nitrite levels 
remained unchanged at the first manifestation of 
T1DM, but decreased 1.7 times in the cytoplasm in 
ND/T patients and about two times in the cytoplasm 
and mitochondria of PBL in patients receiving long-
term insulin treatment.  
Figure 4 shows the sex and age-dependent changes 
in plasma nitrite levels in patients with T1DM. In the 
T1DM-FI group, at the first manifestation of T1DM, 
plasma nitrite level remained unchanged, but decreased 
1.6 and 1.7 times in ND/T and LT/T patients, 
respectively, compared with HC, whereas, in the 
T1DM-FII group, it decreased 1.4 times at the first 
manifestation of T1DM, and normalized by insulin 
therapy, regardless of duration. We suggest that 
processes during puberty may contribute to insulin 
modulation of NO/nitrite production in PBL and 
plasma in females with T1DM. 
In the T1DM-MI group, at the first manifestation 
of diabetes, a twofold increase in plasma nitrite level 
was detected, which normalized in ND/T and LT/T 
patients. In the T1DM-MII group, plasma nitrite level 
decreased 2.2, 2.6, and 2.9 times in ND/NT, ND/T 
and LT/T patients, respectively, compared with HC. 
Thus, in adolescents/young males insulin did not 
prevent a decrease in nitrite levels, regardless of the 
duration of treatment. 
Our findings generally agree with the results, which 
show a fourfold drop in plasma nitrite levels in children 
and adolescents with long-term treated T1DM22. 
However, we found that insulin can modulate plasma 
nitrite levels in adolescents/young females with T1DM, 
unlike males, which indicates that the effectiveness of 
insulin therapy depends on sex and puberty.  
L-citrulline, a byproduct of NOS, is recycled back 
to L-arginine by argininosuccinate synthase and 
argininosuccinate lyase, maintaining its level in many 
tissues and involving in citrulline-NO cycle46. 
Interestingly, in young Caucasians, both healthy and 
with T1DM, the level of plasma L-citrulline was 
about 5 times higher than in PBL, regardless of sex 
and puberty, and vice versa, the level of 
malondialdehyde, a stable product of lipid 
peroxidation and oxidative stress marker was 
significantly higher in PBL than in the plasma 
(unpublished data).  
Figure 5 shows the sex and age-dependent changes 
in the level of L-citrulline in the cellular 
 
 
Fig. 4 — Effect of insulin therapy on nitrite level in peripheral 
blood plasma of patients with T1DM. 
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compartments of PBL in patients with T1DM. In the 
T1DM-FI group, the level of L-citrulline decreased 
1.8, 2.3 and 1.5 times in the cytoplasm and 1.7, 1.8 
and 1.4 times in mitochondria, in ND/NT, ND/T and 
LT/T female patients, respectively, compared with 
HC. This suggests that a decrease in the level of  
L-citrulline in leukocytes decreases with prolonged 
T1DM, however, whether this is a consequence of the 
influence of insulin requires further study. At the 
same time a simultaneous decrease in the levels of 
citrulline and nitrites observed in the compartments of 
PBL indirectly indicates a decrease in the NOS 
activity in children/preadolescent females with 
diabetes. In the T1DM-FII group, L-citrulline 
remained the same level in the cytoplasm and 
mitochondria of PBL before and after insulin 
treatment, regardless of its duration, аnd did not 
correlate with changes in the nitrite content. 
Interestingly, in the T1DM-MI group, the level of 
L-citrulline in the cytoplasm increased by 1.3 and  
1.5 times during the first manifestation of T1DM and 
after prolonged treatment with insulin, respectively, 
compared with HC, whereas in mitochondria it 
remained unchanged, with the exception of ND/T male 
patients, in which it also increased. In the T1DM-MII 
group, citrulline level decreased 1.5 and 1.2 times in 
the cytoplasm and mitochondria of PBL at the first 
manifestation of T1DM and two times in ND/T 
patients, respectively, compared with HC, but returned 
to normal after prolonged treatment with insulin.  
Sex and age-dependent changes in plasma L-citrulline 
levels in patients with T1DM are presented in (Fig. 6). 
In children/preadolescent females with the first 
manifestation of T1DM, plasma L-citrulline level 
remained the same, but decreased 1.4 and 1.6 times in 
ND/T and LT/T patients. In the T1DM-FII group, 
plasma L-citrulline levels also decreased by 1.6 and 
1.9 times in ND/T and LT/T patients, respectively, 
compared with HC. Thus, in both female age groups, 
plasma L-citrulline levels were not influenced by 
insulin, regardless of the duration of treatment. 
Unlike females, in both age groups of male 
patients, plasma citrulline levels generally remained 
the same before and after insulin treatment, regardless 
of duration. 
 
Discussion 
Although, it is commonly known that pancreas is no 
longer viable, and incapable of producing insulin, 
during 1 or 2 years of diagnosis of T1DM, a significant 
proportion of patients with long-term disease have 
measurable levels of serum C-peptide and/or proinsulin 
indicating the presence of substantial β-cell mass that is 
dysfunctional but not destroyed47,48. Based on that, sex 
and age-dependent L-arginine metabolism was studied 
in different duration of T1DM.  
Overactivation of arginase isoforms detected in all 
patients with T1DM, which is probably associated 
with a high level of extracellular D-glucose that 
promotes the activation of NADPH oxidase and 
increases ROS synthesis and L-arginine transport, 
through which it can stimulate the activity and 
 
Fig. 5 — Effect of insulin therapy on L-citrulline level in the cell 
compartments of peripheral blood leukocytes of patients with 
T1DM.   
 
Fig. 6 — Effect of insulin therapy on L-citrulline level in 
peripheral blood plasma of patients with T1DM.  
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expression of arginase isoforms12,49. High arginase 
activity may also be associated with a high coefficient 
of oxidative stress (2.32) in Caucasian patients with 
T1DM50. It can also be assumed that arginase activity 
is stimulated in leukocytes as a response to the 
increase in the growth of Candida albicans in the gut, 
which we detected in patients with T1DM51.Glucose 
concentration is known directly related to the growth 
rate of C. albicans in uncontrolled diabetic patients52. 
Moreover, C. albicans blocks NO production in 
human macrophages and induces arginase activity, 
blocking of which can restore NO production and 
increase macrophage kill potential53. 
Oxidative stress has a negative effect on insulin 
signaling and can be reduced by controlling 
hyperglycemia, which is shared by both type 1 and 
type 2 diabetes, and is a main factor of influencing 
oxidative stress either by the direct generation of ROS 
or by altering redox balance54. Short-term insulin 
pump therapy may significantly suppress oxidative 
stress affecting both ways55. When suppressing 
oxidative stress, insulin can inhibit the activation of 
arginase isoforms, but we were able to observe this 
effect only in adolescent/young females, presumably 
due to female sex hormones involvement in effect of 
insulin. Long-term insulin treatment can effectively 
modulate the activity of both A1 and A2, namely 
normalizes A2 activity and shifts the balance towards 
A1, which is necessary for the anti-inflammatory 
functioning of M2 macrophages, as well as for the 
fungicidal activity of human neutrophils56. In 
children/preadolescent females, long-term treatment 
with insulin does not affect A1 activity, but is 
accompanied by a decrease in A2 activity, which 
though remains two times higher than normal. 
Notably, endogenous estrogen, 17 -estradiol (E2) 
can stimulate the M2 phenotype associated with A1 
activity and inhibit M1 functions in both peripheral 
macrophages and those in the CNS57. E2 is also 
involved in protecting the function/survival of 
pancreatic β-cells and insulin secretion under 
conditions of oxidative stress58. It should be noted that 
in the cytoplasm, the A1-derived ornithine may 
provide proline or glutamate synthesis via ornithine 
aminotransferase, while in mitochondria A2-derived 
ornithine is involved in the synthesis of polyamines 
via ornithine decarboxylase59.It is shown that A2 
promote the inflammatory response of macrophages 
via NOS-independent stimulation of mitochondrial 
ROS, which contribute to insulin resistance and 
atherogenesis60. Recent data suggest that targeting the 
synthesis of polyamines partially protects against 
hyperglycemia by increasing Treg cells crucial for 
immune tolerance and reducing potentially pathogenic 
Th17 cells in the lymph nodes of the pancreas in 
T1DM61. At the same time, A1 can provide myeloid-
derived suppressor cells (MDSCs) effect on the 
development of TH17 cell-associated autoimmunity 
(systemic lupus erythematosus, SLE), therefore 
targeting MDSCs or A1 may offer potential therapeutic 
strategies for treating SLE and other TH17 cell-
mediated autoimmune diseases62. This echoes with the 
fact that a new function of the vascular endothelial 
growth factor (VEGF) receptor 1 signaling is to 
prevent the over-expression of arginase 1, associated 
with over-activation of macrophages, which causes 
autoimmune diseases63. Moreover, the healing of a 
diabetic wound is associated with increased 
neovascularization and tissue regeneration, which 
correlates with VEGF and the mitogen-activated protein 
kinase pathway, and endothelial nitric oxide synthase in 
streptozotocin-induced diabetes64. It was also found that 
the insertion/deletion gene polymorphism in the VEGF 
promoter region may play a role in the development of 
non-diabetic nephropathy65. However, nephropathy can 
eventually develop in both types of diabetes, taking into 
account the glycemic and genetic background66. 
Unlike females, children/preadolescent males who 
underwent prolonged insulin treatment, exhibit higher 
activity of arginase isoforms in PBL compared with 
patients who have received insulin for one year. 
Insulin also did not prevent an increase in arginase 
activity in adolescents/young male patients, regardless 
of the duration of treatment. This can aggravate the 
course of T1DM, especially since isoforms of 
arginase may contribute to the development of 
oxidative stress by local depletion of L-arginine, 
which leads to the forced simultaneous production of 
NO and superoxide through NOS and further 
peroxynitrite followed by peroxynitrite-mediated cell 
damage67,68. It should be also noted that signalling 
pathways involving endothelial and inducible NOS 
isoforms/NO, NADPH oxidase, and arginase could 
play key roles in chronic diabetes mellitus-associated 
cardiovascular abnormalities reviewed elsewhere38,69. 
Preventing these signalling alterations can also protect 
from the development of cardiovascular disease 
associated with diabetes. 
It is commonly known that high arginase activity 
may reduce NO production, which leads to the 
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development of microvascular complications in 
diabetes70. Arginase can suppress the activity of NOS 
either by reducing the intracellular level of L-arginine 
or by producing urea, which inhibits the dimerization 
of NOS monomers71. Our data have shown that the 
activation of arginase isoforms in T1DM is 
accompanied by changes in the level of nitrite and 
citrulline, which are sex and age- dependent. So, in 
prepubertal females, levels of nitrite and citrulline are 
reduced in the cytoplasm and mitochondria of PBL at 
the first manifestation of T1DM, which possibly 
associated with suppression of the endogenous NO 
production. In adolescent/young female patients 
increased levels of estrogen and other sex hormones 
can upregulate NOS, particularly in leukocytes72. So, 
E2 can increase the ability of human neutrophils to 
produce NO and, therefore, contribute to the protection 
against cardiovascular disease73. Endothelial NOS 
(eNOS), in addition to the well-known estrogen-
dependent stimulation, is constitutively expressed in 
humans in a sex-specific innate manner, namely, female 
endothelial cells express more eNOS mRNA and 
protein than men, both in vitro, and ex vivo74. 
Nitrites increased markedly in the cellular 
compartments of PBL and plasma in children/ 
preadolescent males with the first manifestation of 
T1DM and decreased during treatment with insulin. 
Interestingly, the nitrite level remained unchanged in 
the cellular compartments of PBL in adolescents/ 
young males with T1DM, and treatment with insulin 
reduced it below normal. It can be speculated that an 
increase in nitrite levels in PBL and plasma in 
prepubertal boys with T1DM may be associated with 
lower oxidative stress compared with adolescents/ 
young males. It is noteworthy that nanomolar 
concentrations of NO can promote cGMP-dependently 
glucose-induced [Ca2+]i oscillations and insulin 
secretion in β-cells and inhibit at submicromolar 
concentrations independently of cGMP75. Recent data 
suggest that NOS/NO may contribute to β-cell 
survival via selective suppression of DNA damage-
response signaling and apoptosis, although NO cannot 
inhibit it in macrophages, hepatocytes, and 
fibroblasts76. Interestingly, NO readily reacts with 
cysteine residues in the key active site of both  
L-ornithine- and S-adenosyl methionine decarboxylases 
and inactivates the synthesis of polyamines, mediating 
anti-proliferative activity77. 
Limiting L-arginine can be improved with dietary 
supplements or by intravenous administration of 
arginine or its endogenous precursor citrulline, which 
also increases insulin sensitivity78. L-citrulline  
can enhance the formation of NO and suppress  
the activity of arginase, as its allosteric inhibitor79.  
It should be noted that changes in the level of 
citrulline are not directly dependent on the activity  
of NOS. The decrease in citrulline can be explained 
by its conversion to arginine, which in turn is 
metabolized by activated arginase, followed by 
depletion of arginine in plasma of diabetics.  
In addition, citrulline is produced by ornithine 
transcarbamylase, and even a slight deficiency  
of which is accompanied by a decrease in plasma 
levels of citrulline and arginine80. L-citrulline  
levels decreased in the cytoplasm and mitochondria of 
PBL and plasma in children/preadolescent females 
with T1DM, and slightly depended on the duration of 
insulin treatment. At the same time citrulline levels 
were less reduced in the cellular compartments in 
children/preadolescent males with T1DM than in 
adolescents/young ones, and long-term treatment with 
insulin completely restored it, regardless of age. It is 
important because L-citrulline can also restore the 
NO/ROS balance and play a protective role in T1DM 
as was shown in a mouse model of streptozotocin-
induced diabetes81. In general, the effect of insulin 
therapy on sex and age- associated changes in the 
activity of arginase isoforms and levels of NOS 
metabolites in PBL and plasma of patients with 
T1DM may be partially related to the regulation of 
insulin functions via sex hormones directly through 
insulin-sensitive tissues and indirectly through 
oxidative stress45. 
 
Conclusion 
Results of this study suggest that the activation of 
functionally different arginase isoforms and a 
corresponding decrease in the levels of nitric oxide 
synthase products, stable NO metabolites (nitrite) and 
citrulline in the cytoplasm and mitochondria in the 
peripheral blood leukocytes of young Caucasians with 
type 1 diabetes depend on sex and age, in particular 
puberty. Subcellular perturbations of L-arginine 
metabolic pathways in PBLare more pronounced in 
women than in men, and they are effectively 
modulated by insulin treatment in women, depending 
on the duration of insulin therapy, especially during 
puberty, presumably due to an increased level of 
estrogens that affect the metabolism of L arginine and 
insulin effects. In male patients, prolonged insulin 
therapy does not prevent hyperactivation of arginase 
isoforms and, accordingly, a decrease in the level of 
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nitrite, most pronounced in boys of puberty. Further 
research is needed to understand whether the sex and 
age-related changes observed in L-arginine 
metabolism in PBL can be useful for assessing the 
stage and progression of type 1 diabetes and the 
effectiveness of therapy, as well as to understand 
whether this should be taken into account in the 
differential targeting of arginase isoforms and 
nitrergic system for a beneficial effect on the course 
of type 1 diabetes. 
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